DW6015

DW6015 is a Dongwha Pharmaceutical fixed-dose oral antidiabetic combination containing **empagliflozin** and **extended-release metformin** for **type 2 diabetes mellitus**. Empagliflozin inhibits sodium-glucose cotransporter 2 in the renal proximal tubule, increasing urinary glucose excretion, while metformin reduces hepatic glucose production and improves insulin sensitivity. Dongwha describes DW6015 as an incrementally modified drug that combines two diabetes medicines and converts an immediate-release component to a sustained-release formulation; public reporting identifies DW6015 and DW6014 as empagliflozin-metformin combination products that received Korean marketing authorization in April 2025. ([dong-wha.co.kr](https://www.dong-wha.co.kr/english/rnd/rnd06.asp))